Showing results (101-110 of 157) with videos related to
Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101Antonius A Miller, Daryl J Murry, Kouros Owzar, et al.Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.Cancer Chemotherapy and Pharmacology|January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerRamesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.Annals of Surgical Oncology|February 19, 2024
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden RiskVarun V Bansal, Owen Mitchell, Celyn Bregio, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2016
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural MesotheliomaAnna K Nowak, Kari Chansky, David C Rice, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 8, 2026
Germline genetic testing and privacy concerns in patients with mesotheliomaOwen D Mitchell, Abigail P Sneider, Katie Gilliam, et al.Quantitative Imaging in Medicine and Surgery|March 28, 2024
Implementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesotheliomaMilica Medved, Hunter D D Witmer, Ankit Dhiman, et al.Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.Pageof 16